Trieu Calvin, van Leeuwenstijn Mardou S S A, Schlüter Lisa-Marie, Ebenau Jarith L, Verberk Inge M W, Sikkes Sietske A M, Verfaillie Sander C J, van de Giessen Elsmarieke, Teunissen Charlotte E, van der Flier Wiesje M, van Harten Argonde C
Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Center (UMC) location Vrije Universiteit Medical Center (VUmc), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
Front Psychiatry. 2025 Jun 10;16:1572174. doi: 10.3389/fpsyt.2025.1572174. eCollection 2025.
Depressive/anxiety symptoms are common in subjective cognitive decline (SCD) and may relate to Alzheimer's pathology, potentially modulated by personality characteristics.
Depressive/anxiety symptoms were assessed over 4 ± 2 years in 329 SCD (88 amyloid-positive/241 amyloid-negative) using Geriatric Depression Scale-15 (GDS), Center for Epidemiological Studies-Depression (CES-D), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Mixed-effects models assessed associations between amyloid status and these symptoms, with neuroticism and somatization as effect-modifiers.
Amyloid status was not directly associated with GDS, CES-D or HADS-A. However, neuroticism modified the association between amyloid status and GDS (p<0.05). In lower neuroticism, amyloid positivity was associated with GDS increase (β:0.10 ± 0.08), but not in higher neuroticism (β:-0.04 ± 0.12). Somatization modified the association between amyloid status and CES-D (p<0.05). In lower somatization, amyloid positivity was associated with CES-D increase (β:0.65 ± 0.23), but not in higher somatization (β:-0.12 ± 0.29).
Amyloid-positive individuals with lower neuroticism/somatization increased more in depressive symptoms over time, suggesting a preclinical AD-related depressive phenotype.
抑郁/焦虑症状在主观认知下降(SCD)中很常见,可能与阿尔茨海默病病理学有关,可能受人格特征调节。
使用老年抑郁量表15(GDS)、流行病学研究中心抑郁量表(CES-D)和医院焦虑抑郁量表-焦虑分量表(HADS-A),对329例SCD患者(88例淀粉样蛋白阳性/241例淀粉样蛋白阴性)进行了4±2年的抑郁/焦虑症状评估。混合效应模型评估了淀粉样蛋白状态与这些症状之间的关联,并将神经质和躯体化作为效应修饰因素。
淀粉样蛋白状态与GDS、CES-D或HADS-A无直接关联。然而,神经质改变了淀粉样蛋白状态与GDS之间的关联(p<0.05)。在低神经质组中,淀粉样蛋白阳性与GDS升高相关(β:0.10±0.08),但在高神经质组中则不然(β:-0.04±0.12)。躯体化改变了淀粉样蛋白状态与CES-D之间的关联(p<0.05)。在低躯体化组中,淀粉样蛋白阳性与CES-D升高相关(β:0.65±0.23),但在高躯体化组中则不然(β:-0.12±0.29)。
神经质/躯体化程度较低的淀粉样蛋白阳性个体随时间推移抑郁症状增加更多,提示存在一种与临床前期阿尔茨海默病相关的抑郁表型。